446-38-8

Basic information

• Product Name: 3-Fluoro-4-nitroanisole
• Synonyms: 3-FLUORO-4-NITROANISOLE;2-Fluoro-4-methoxy-1-nitrobenzene;2-Fluoro-4-methoxynitrobenzene;2-Fluoro-4-methoxynitrobenzene, 3-Fluoro-4-nitrophenyl methyl ether;3-Fluoro-4-nitroanisole 98%;Anisole, 3-fluoro-4-nitro-
• CAS NO: 446-38-8
• Molecular Formula: C₇H₆FNO₃
• Molecular Weight: 171.13
• EINECS: 1312995-182-4
• Product Categories: blocks;FluoroCompounds;NitroCompounds;Aromatic Halides (substituted)
• Mol File: 446-38-8.mol

Chemical Properties

• Melting Point: 57.3
• Boiling Point: 264.5 °C at 760 mmHg
• Flash Point: 113.7 °C
• Appearance: /
• Density: 1.321 g/cm³
• Vapor Pressure: 0.0159mmHg at 25°C
• Refractive Index: 1.521
• Storage Temp.: Keep Cold
• CAS DataBase Reference: 3-Fluoro-4-nitroanisole(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Fluoro-4-nitroanisole(446-38-8)
• EPA Substance Registry System: 3-Fluoro-4-nitroanisole(446-38-8)

Safety Data

• Hazard Codes: Xi,C
• Statements: 34
• Safety Statements: 26-36/37/39-45
• RIDADR: 3261
• HazardClass: 8
• PackingGroup: Ⅱ
• Hazardous Substances Data: 446-38-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-Fluoro-4-nitroanisole is used as a synthetic intermediate for the development of various pharmaceuticals. Its unique structure allows for the creation of new drug candidates with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, 3-Fluoro-4-nitroanisole is employed as a precursor in the synthesis of novel agrochemicals. Its incorporation into these compounds can lead to the development of more effective and targeted pest control agents.
Used in Organic Chemistry Research:
3-Fluoro-4-nitroanisole serves as a valuable research tool in organic chemistry, enabling scientists to explore new reaction pathways and mechanisms. Its presence in various chemical reactions can provide insights into the behavior of similar compounds and contribute to the advancement of synthetic methodologies.

InChI:InChI=1/C7H6FNO3/c1-12-5-2-3-7(9(10)11)6(8)4-5/h2-4H,1H3

Upstream product

• 394-41-2 3-fluoro-4-nitrophenol 
• 77-78-1 dimethyl sulfate 
• 100-17-4 para-methoxynitrobenzene 
• 446-35-5 2,4-Difluoronitrobenzene 
• 865-33-8 potassium methanolate 
• 124-41-4 sodium methylate 
• 74-88-4 methyl iodide 
• 372-20-3 3-fluorophenol 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 67-56-1 methanol 

Downstream Products

• 458-52-6 2-fluoro-4-(methoxy)aniline 
• 394-18-3 1-fluoro-5-methoxy-2,4-dinitrobenzene 
• 140381-69-7 N-(2-nitro-5-methoxyphenyl)-1,2,3,4-tetrahydroisoquinoline 
• 98447-16-6 dimethyl-2,5 nitro-2' methoxy-5' diphenylamine 
• 98447-11-1 (methoxy-5' nitro-2' anilino)-6 dimethyl-5,8 isoquinoleine 
• 97655-38-4 ethyl α-cyano-5-methoxy-2-nitrobenzene acetate 
• 109005-38-1 4-methoxy-2-<<(4-methylphenyl)sulfonyl>methyl>-1-nitrobenzene 
• 781647-79-8 (2S,5R)-2-tert-butyl-5-(5-methoxy-2-nitrophenyl)-5-phenyl-1,3-dioxolan-4-one 
• 950772-36-8 1-[trans-4-(ethyloxy)cyclohexyl]-N-[5-(methyloxy)-2-nitrophenyl]-4-piperidinamine 
• 781647-91-4 (R)-5-methoxy-2-nitrobenzilic acid 
• 213627-32-8 dimethyl 2-(5-methoxy-2-nitrophenyl)malonate 

Relevant articles and documents

Efficient enantioselective total synthesis of (-)-horsfiline

A new efficient and concise enantioselective synthetic method for (-)-horsfiline is reported. (-)-Horsfiline could be obtained from diphenylmethyl tert-butyl malonate in 9 steps (32 %,>99 % ee) by using the enantioselective phase-transfer catalytic allylation (91 % ee) as the key step. This approach can be applied as a practical route for the large-scale synthesis of spirooxindole natural products, which enables a systematic investigation of their biological activity to be performed. Practical synthesis of a spirooxindole: The total synthesis of (-)-horsfiline was accomplished from diphenylmethyl tert-butylmalonate in nine steps (32 %, >99 % ee) by using a enantioselective phase-transfer catalytic allylation (91 % ee) as the key step (see scheme). Copyright

Synthesis of near-infrared fluorescent rhodamines via an SNArH reaction and their biological applications

Near-infrared (NIR) dyes are of great interest in biomedicine due to diminished interfering absorption and fluorescence from biological samples, reduced scattering, and enhanced tissue penetration depth. In this context, we report the synthesis of rectili

Quinoxaline compound, preparation method and application of quinoxaline compound in medicine

The invention provides a quinoxaline compound, a preparation method and application of the quinoxaline compound in medicine, and particularly relates to a quinoxaline compound with PAR4 antagonistic activity, a preparation method of the quinoxaline compound, a pharmaceutical composition containing the quinoxaline compound and application of the quinoxaline compound. Specifically, the invention provides a compound shown as a general formula I and/or II or a tautomer or pharmaceutically acceptable salt thereof, a preparation method of the compound, and application of the compound or the tautomer or the pharmaceutically acceptable salt in medicines for preventing and/or treating thromboembolic diseases.

FUSED RING HETEROARYL COMPOUNDS AS RIPK1 INHIBITORS

The invention provides novel substituted heterocyclic compounds represented by Formula I, or a pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof, and a composition comprising these compounds. The compounds provided c

Synthesis and evaluation of novel and potent protease activated receptor 4 (PAR4) antagonists based on a quinazolin-4(3H)-one scaffold

Protease activated receptor 4 (PAR4) is an important target in antiplatelet therapy to reduce the risk of heart attack and thrombotic complications in stroke. PAR4 antagonists can prevent harmful and stable thrombus growth, while retaining initial thrombus formation, by acting on the late diffusion stage of platelet aggregation, and may provide a safer alternative to other antiplatelet agents. To date, only two PAR4 antagonists, BMS-986120 and BMS-986141 have entered clinical trials for thrombosis. Thus, the development of a potent and selective PAR4 antagonist with a novel chemotype is highly desirable. In this study, we explored the activity of quinazolin-4(3H)-one-based PAR4 antagonists, beginning with their IDT analogues. By repeated structural optimisation, we developed a series of highly selective PAR4 antagonists with nanomolar potency on human platelets. Of these, 13 and 30g, with an 8-benzo[d]thiazol-2-yl-substituted quinazolin-4(3H)-one structure, showed optimal activity (h. PAR4-AP PRP IC50 = 19.6 nM and 6.59 nM, respectively) on human platelets. Furthermore, 13 and 30g showed excellent selectivity for PAR4 versus PAR1 and other receptors (IC50s > 10 μM) on human platelets. And 13 and 30g were lack of cross-reactivity for PAR1 or PAR2 (PAR1 AP FLIPR IC50 > 3162 nM, PAR2 AP FLIPR IC50 > 1000 nM) in the calcium mobilization assays. Metabolic stability assays and cytotoxicity tests of 13 and 30g indicated that these compounds could sever as promising drug candidates for the development of novel PAR4 antagonists. In summary, the quinazolin-4(3H)-one-based analogues are the first reported chemotypes with excellent activity and selectivity against PAR4, and, in the current study, we expanded the structural diversity of PAR4 antagonists. The two compounds, 13 and 30g, found in our study could be promising starting points with great potential for further research in antiplatelet therapy.

Benzotriazine compound with PAR4 antagonistic activity and application thereof

The invention discloses a benzotriazine compound with PAR4 antagonistic activity and application thereof. The present invention relates to a compound of formula (I) or a stereoisomer, tautomer, pharmaceutically acceptable salt, ester, solvate or prodrug t

Method for synthesizing 3-fluoro-4-aminophenol

The invention provides a method for synthesizing 3-fluoro-4-aminophenol. The method comprises the following steps: (1) preparing a composite catalyst from nickel nitrate, palladium chloride and butyl titanate through a sol-gel method; (2) enabling metallic sodium and 2,4-difluoronitrobenzene and methanol to react so as to prepare 2-fluoro-4-methoxyl-nitrobenzene; (3) performing a demethylation reaction on 2-fluoro-4-methoxyl-nitrobenzene through aluminum chloride so as to prepare 3-fluoro-4-nitrophenol; (4) performing a catalytic hydrogenation reaction on the 3-fluoro-4-nitrophenol by using a composite catalyst, thereby obtaining 3-fluoro-4-aminophenol. The method is relatively high in yield, and the product is also relatively high in purity.

BENZIMIDAZOLE DERIVATIVES AND USES THEREOF

Benzimidazole derivatives of Formula I, that modulate the activity of ACSS2 are disclosed for therapeutic use. The fused imidazole ring of the compounds disclosed has a diarylmethyl or diarylmethanol moiety attached at the 2-position and the compounds have at least one other substituent at the 5 or 6 position of the benzimidazole. Also disclosed are methods of using the benzimidazole compounds for the treatment of diseases or disorders, such as cancer.

A Fast Way to Fluorescence: A Fourfold Domino Reaction to Condensed Polycyclic Compounds

A fast and efficient palladium-catalyzed fourfold domino Sonogashira/double-carbopalladation/C H-activation reaction that converts simple aromatic systems into complex polycyclic hydrocarbons has been developed. A number of substituted products has thus been prepared in yields up to 89 %. The structural assignment has been confirmed by using single-crystal X-ray crystallography. The products show intriguing fluorescence activity and thus might serve as chemical sensors or fluorescent imaging dyes.

WNT PATHWAY ANTAGONISTS

The present invention relates to novel compounds of formula (I): as herein described and pharmaceutical compositions thereof. The compounds of formula (I) have inhibitory effect on the Wnt pathway and are therefore useful in the preparation of a medicament, in particular for the treatment of cancer.